RNF43 and Marinesco-Sjogren syndrome: Clinically, mutations in RNF43 predicted improved response rates and survival outcomes in MSS patients, with median PFS in the MSS-RNF43 mutated group being 10.1 months (versus 4.1 months in the MSS-RNF43 wild-type group) [15].